Acadia slides as SA article paints grim picture

Shares of Acadia Pharmaceuticals (ACAD -3.3%) are flagging and are now sitting at their lows of the day.

Earlier, SA contributor EnhydrisPECorp named ACAD a "healthcare stock to avoid" in 2014, saying the shares may "bleed all year long until the [pimavanserin] NDA filing in Q4."

Here's the simple rationale for the author's downbeat outlook: "Firstly, the company now has a market cap over $2B. Secondly, ACAD has no revenues. Thirdly, ACAD has mounting clinical trial costs."

Notably, EnhydrisPECorp recommended investors short Sarepta Therapeutics on October 30 — since then, the stock is down 54%.

From other sites
Comments (10)
  • User 17130542
    , contributor
    Comment (1) | Send Message
    Hard to believe SA would publish article 3 months ago projecting ACAD to go to $300/sh and now how this "avoid" rating . New projection by SA .. this stock will go up or down , at least we think it will , maybe.
    7 Jan 2014, 01:06 PM Reply Like
  • User 13728572
    , contributor
    Comment (1) | Send Message
    What if ACAD is acquired before the Q4 filing? I guess that's the risk of staying out of the stock.
    7 Jan 2014, 01:41 PM Reply Like
  • Pokeysun
    , contributor
    Comment (1) | Send Message
    i was very disappointed in your article in regards to ACAD
    there was not much substance and alot are questioning your negative article including myself..
    7 Jan 2014, 02:32 PM Reply Like
  • User 5877231
    , contributor
    Comments (225) | Send Message
    I hope they knock it down to $20-21 so I can buy in aggressively. Seriously, we all know there's no + revenue right now nor will there be in 2014.
    7 Jan 2014, 05:05 PM Reply Like
  • fafatooey
    , contributor
    Comments (435) | Send Message
    I agree with this. Sold this morning after a three-bagger. Will check back in at the end of the summer and hopefully pick it back up in the teens. GO SEAHAWKS!.
    7 Jan 2014, 05:05 PM Reply Like
  • johnnyhaha
    , contributor
    Comments (226) | Send Message
    Why don't you write that EnhydrisPECorp recommended shorting ACAD in April of 2013 and they are now down over 80%.
    7 Jan 2014, 08:00 PM Reply Like
  • spivak2000
    , contributor
    Comment (1) | Send Message
    I bought ACAD in April 2013 for under 13. How is it now down over 80%?
    7 Jan 2014, 10:29 PM Reply Like
  • hancharou
    , contributor
    Comments (18) | Send Message
    ACAD is very strong stock that is backed by The Baker Brothers and other strong institutions.
    All pharma stocks fluctuate a lot. You should keep in mind that ACAD has drug that address unmet medical needs, the NDA will be backed by strong Phase I/II results, I even believe that it could be approved a bit earlier. Let say in Q3. I'm not talking about acquisition.
    7 Jan 2014, 09:46 PM Reply Like
  • bobsar
    , contributor
    Comments (402) | Send Message
    Of course it has no revenue now. This is a silly write up. Revenue can't happen until 2015.
    7 Jan 2014, 10:04 PM Reply Like
  • Clinically Sound Investor
    , contributor
    Comments (323) | Send Message
    Wow, shows the "quality" of SA to be touting their alleged influence on the markets, especially with a hack job author like EnhydrisPECorp. Yes, he had some investment successes as well as correct predictions, but it's his reasoning behind his picks that are suspect. He's like SA's armchair version of The Street's Adam Feuerstien.
    8 Jan 2014, 10:15 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs